SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. You have free access to this content1
    Tarik Asselah, Patrick Marcellin, Optimal IFN-free therapy in treatment-naïve patients with HCV genotype 1 infection, Liver International, 2015, 35,
  2. You have free access to this content2
    Tarik Asselah, Patrick Marcellin, Viral hepatitis: towards the eradication of HCV and a cure for HBV, Liver International, 2015, 35,
  3. You have free access to this content3
    L. I. Backus, P. S. Belperio, T. A. Shahoumian, R. Cheung, L. A. Mole, Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort, Alimentary Pharmacology & Therapeutics, 2014, 39, 1
  4. 4
    Hugh Adler, John S Lambert, Daclatasvir for the treatment of hepatitis C virus infection, Expert Review of Gastroenterology & Hepatology, 2014, 8, 7, 725

    CrossRef

  5. 5
    Daclatasvir plus Sofosbuvir for HCV Infection, New England Journal of Medicine, 2014, 370, 16, 1560

    CrossRef

  6. 6
    Warren N. Schmidt, David R. Nelson, Jean–Michel Pawlotsky, Kenneth E. Sherman, David L. Thomas, Raymond T. Chung, Direct-Acting Antiviral Agents and the Path to Interferon Independence, Clinical Gastroenterology and Hepatology, 2014, 12, 5, 728

    CrossRef

  7. 7
    EASL Clinical Practice Guidelines: Management of hepatitis C virus infection, Journal of Hepatology, 2014, 60, 2, 392

    CrossRef

  8. 8
    EASL Recommendations on Treatment of Hepatitis C 2014, Journal of Hepatology, 2014, 61, 2, 373

    CrossRef

  9. You have free access to this content9
    Raymond Schinazi, Philippe Halfon, Patrick Marcellin, Tarik Asselah, HCV direct-acting antiviral agents: the best interferon-free combinations, Liver International, 2014, 34,
  10. 10
    Maria Buti, Rafael Esteban, Hepatitis C virus genotype 3: a genotype that is not ‘easy-to-treat’, Expert Review of Gastroenterology & Hepatology, 2014, 1

    CrossRef

  11. 11
    Andreas Kyvernitakis, Madeleine Duvic, Parag Mahale, Harrys A. Torres, Interferon-Based Treatment for Patients with Mycosis Fungoides and Hepatitis C Virus Infection: A Case Series, American Journal of Clinical Dermatology, 2014, 15, 5, 451

    CrossRef

  12. 12
    F. Poordad, K. Agarwal, Z. Younes, D. Cohen, W. Xie, T. Podsadecki, Low Relapse Rate Leads to High Concordance of Sustained Virologic Response (SVR) at 12 Weeks With SVR at 24 Weeks After Treatment With ABT-450/Ritonavir, Ombitasvir, and Dasabuvir Plus Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection in the AVIATOR Study, Clinical Infectious Diseases, 2014,

    CrossRef

  13. 13
    Andres F Carrion, Julio Gutierrez, Paul Martin, New antiviral agents for the treatment of hepatitis C: ABT-450, Expert Opinion on Pharmacotherapy, 2014, 15, 5, 711

    CrossRef

  14. 14
    Namiki Izumi, Norio Hayashi, Hiromitsu Kumada, Takeshi Okanoue, Hirohito Tsubouchi, Hiroshi Yatsuhashi, Mai Kato, Rito Ki, Yuji Komada, Chiharu Seto, Shoichiro Goto, Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies, Journal of Gastroenterology, 2014, 49, 5, 941

    CrossRef

  15. 15
    Rima A. Mohammad, Marilyn N. Bulloch, Juliana Chan, Paulina Deming, Bryan Love, Lisa Smith, Betty J. Dong, Provision of Clinical Pharmacist Services for Individuals With Chronic Hepatitis C Viral Infection, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2014, 34, 12
  16. 16
    Stefan Christensen, Anton Gillessen, Response to peginterferon plus ribavirin and subsequent retreatment with telaprevir-based triple therapy in a patient with chronic lymphocytic leukaemia and chronic HCV genotype 1b infection, Infectious Agents and Cancer, 2014, 9, 1, 10

    CrossRef

  17. 17
    Youngmin A. Lee, Scott L. Friedman, Reversal, maintenance or progression: What happens to the liver after a virologic cure of hepatitis C?, Antiviral Research, 2014, 107, 23

    CrossRef

  18. You have free access to this content18
    Tarik Asselah, Patrick Marcellin, Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir, Liver International, 2014, 34,
  19. 19
    Tarik Asselah, Sofosbuvir for the treatment of hepatitis C virus, Expert Opinion on Pharmacotherapy, 2014, 15, 1, 121

    CrossRef

  20. You have free access to this content20
    Valérie Martel-Laferrière, Douglas T. Dieterich, Treating HCV in HIV 2013: on the cusp of change, Liver International, 2014, 34,
  21. 21
    Peter Ferenci, Viral hepatitis: Cure of chronic hepatitis C—required length of follow-up?, Nature Reviews Gastroenterology & Hepatology, 2014,

    CrossRef

  22. You have free access to this content22
    Patrick Marcellin, Tarik Asselah, Viral hepatitis: Impressive advances but still a long way to eradication of the disease, Liver International, 2014, 34,
  23. 23
    Tasuku Hara, Norio Akuta, Fumitaka Suzuki, Hitomi Sezaki, Yoshiyuki Suzuki, Tetsuya Hosaka, Masahiro Kobayashi, Mariko Kobayashi, Satoshi Saitoh, Hiromitsu Kumada, A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C, Journal of Medical Virology, 2013, 85, 10
  24. 24
    Tarik Asselah, ABT-450 combined with ritonavir, in addition to ABT-333 and ribavirin: A race for an interferon-free regimen to cure HCV infection, Journal of Hepatology, 2013, 59, 4, 885

    CrossRef

  25. 25
    Jianmeng Chen, Jeffry Florian, Wendy Carter, Russell D. Fleischer, Thomas S. Hammerstrom, Pravin R. Jadhav, Wen Zeng, Jeffrey Murray, Debra Birnkrant, Earlier Sustained Virologic Response End Points for Regulatory Approval and Dose Selection of Hepatitis C Therapies, Gastroenterology, 2013, 144, 7, 1450

    CrossRef

  26. 26
    Susanne Beckebaum, Iyad Kabar, Vito R. Cicinnati, Hepatitis B and C in liver transplantation: new strategies to combat the enemies, Reviews in Medical Virology, 2013, 23, 3
  27. You have free access to this content27
    Tarik Asselah, Patrick Marcellin, Interferon free therapy with direct acting antivirals for HCV, Liver International, 2013, 33,
  28. 28
    Etienne Brochot, Ghassan Riachi, Jean-Christophe Plantier, Catherine Guillemard, Astrid Vabret, Philippe Mathurin, Eric Nguyen-Khac, Gilles Duverlie, Kinetics of relapse after pegylated interferon and ribavirin therapy for chronic hepatitis C, Journal of Medical Virology, 2013, 85, 7
  29. You have free access to this content29
    Patrick Marcellin, Tarik Asselah, Treatment of viral hepatitis: a new era, Liver International, 2013, 33,
  30. 30
    M. F. Donato, A. J. Bastiampillai, M. Manini, S. Monico, Twelve week post-treatment undetectable hepatitis C virus (HCV)-RNA by PCR assay predicts a sustained virological response to anti-HCV therapy independently from immunological status of the infected patients, Journal of Antimicrobial Chemotherapy, 2013, 68, 4, 974

    CrossRef

  31. 31
    José A. Mira, Juan Macías, ¿Podemos adelantar el diagnóstico de la respuesta virológica sostenida a las 12 semanas tras finalizar el tratamiento frente al VHC?, Enfermedades Infecciosas y Microbiología Clínica, 2012, 30, 1, 1

    CrossRef

  32. 32
    Tarik Asselah, A revolution in HCV treatment with direct-acting antivirals: From non-response to eradication, Journal of Hepatology, 2012, 57, 2, 455

    CrossRef

  33. 33
    Masao Omata, Tatsuo Kanda, Ming-Lung Yu, Osamu Yokosuka, Seng-Gee Lim, Wasim Jafri, Ryosuke Tateishi, Saeed S. Hamid, Wan-Long Chuang, Anuchit Chutaputti, Lai Wei, Jose Sollano, Shiv Kumar Sarin, Jia-Horng Kao, Geoffrey W. McCaughan, APASL consensus statements and management algorithms for hepatitis C virus infection, Hepatology International, 2012, 6, 2, 409

    CrossRef

  34. 34
    Alessio Aghemo, Pietro Lampertico, Massimo Colombo, Assessing long-term treatment efficacy in chronic hepatitis B and C: Between evidence and common sense, Journal of Hepatology, 2012, 57, 6, 1326

    CrossRef

  35. 35
    Stanislas Pol, Reem H Ghalib, Vinod K Rustgi, Claudia Martorell, Greg T Everson, Harvey A Tatum, Christophe Hézode, Joseph K Lim, Jean-Pierre Bronowicki, Gary A Abrams, Norbert Bräu, David W Morris, Paul J Thuluvath, Robert W Reindollar, Philip D Yin, Ulysses Diva, Robert Hindes, Fiona McPhee, Dennis Hernandez, Megan Wind-Rotolo, Eric A Hughes, Steven Schnittman, Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial, The Lancet Infectious Diseases, 2012, 12, 9, 671

    CrossRef

  36. 36
    Tarik Asselah, Interferon Stimulated Genes and Hepatitis C Virus Infection, Journal of Interferon & Cytokine Research, 2012, 32, 12, 557

    CrossRef

  37. 37
    José-A Girón-González, María-José Márquez, Mercedes Márquez, Sara Corchado, María-José Soto, Andrés Martín-Aspas, Monserrat Montes De Oca, Francisca Guerrero, Clotilde Fernández-Gutiérrez, La valoración de RNA del virus de la hepatitis C realizada a las 12 semanas de finalizar el tratamiento predice la respuesta virológica sostenida en enfermos con coinfección por VIH y VHC, Enfermedades Infecciosas y Microbiología Clínica, 2012, 30, 1, 15

    CrossRef

  38. 38
    Masashi Namikawa, Satoru Kakizaki, Yutaka Yata, Yuichi Yamazaki, Norio Horiguchi, Ken Sato, Hitoshi Takagi, Masatomo Mori, Optimal follow-up time to determine the sustained virological response in patients with chronic hepatitis C receiving pegylated-interferon and ribavirin, Journal of Gastroenterology and Hepatology, 2012, 27, 1
  39. 39
    Dauana O. Bastos, Renata M. Perez, Ivonete Souza Silva, Lara Barros Lemos, José Pascoal Simonetti, José Osmar Medina-Pestana, Antonio Eduardo B. Silva, Maria Lucia Ferraz, Transcription-mediated amplification (TMA) for the assessment of viremia in hemodialysis patients with hepatitis C, Journal of Medical Virology, 2012, 84, 4
  40. 40
    Tarik Asselah, Triple therapy with boceprevir or telaprevir for prior HCV non-responders, Best Practice & Research Clinical Gastroenterology, 2012, 26, 4, 455

    CrossRef

  41. 41
    Isabel Campos-Varela, Lluis Castells, Juan Ignacio Esteban, Marta Bes, Francisco Rodríguez-Frías, Gonzalo Sapisochin, Helena Allende, Ramón Charco, Rafael Esteban, Twelve-Week Posttreatment Follow-Up to Predict Sustained Virologic Response for Recurrent Hepatitis C Infection in Liver Recipients, Transplantation, 2012, 93, 4, 450

    CrossRef

  42. 42
    Vincent Soriano, Eugenia Vispo, Luz Martin-Carbonero, Pablo Barreiro, HCV and HIV Coinfection, Current Hepatitis Reports, 2011, 10, 1, 52

    CrossRef

  43. You have free access to this content43
    Philipp de Leuw, Christoph Sarrazin, Stefan Zeuzem, How to use virological tools for the optimal management of chronic hepatitis C, Liver International, 2011, 31,
  44. You have free access to this content44
    Alfredo Alberti, Impact of a sustained virological response on the long-term outcome of hepatitis C, Liver International, 2011, 31,
  45. 45
    Tarik Asselah, NS5A inhibitors: A new breakthrough for the treatment of chronic hepatitis C, Journal of Hepatology, 2011, 54, 5, 1069

    CrossRef

  46. 46
    B. L. Pearlman, N. Traub, Sustained Virologic Response to Antiviral Therapy for Chronic Hepatitis C Virus Infection: A Cure and So Much More, Clinical Infectious Diseases, 2011, 52, 7, 889

    CrossRef

  47. 47
    A. Rivero-Juarez, J. A. Mira, I. Perez-Camacho, J. Macias, A. Camacho, K. Neukam, J. Torre-Cisneros, N. Merchante, J. A. Pineda, A. Rivero, Twelve week post-treatment follow-up predicts sustained virological response to pegylated interferon and ribavirin therapy in HIV/hepatitis C virus co-infected patients, Journal of Antimicrobial Chemotherapy, 2011, 66, 6, 1351

    CrossRef

  48. 48
    Tatehiro Kagawa, Emmet B. Keeffe, Long-Term Effects of Antiviral Therapy in Patients with Chronic Hepatitis C, Hepatitis Research and Treatment, 2010, 2010, 1

    CrossRef